Young medico's campaign brings smart school to Rajasthan's Chambal ravines
The Rajghat village in Dholpur district is deprived of the benefits of schemes designed for panchayats because of its location in the municipal limits. The 'Save Rajghat Campaign' of Ashwani Parashar, 28, first brought electricity to the village with a population of just 350 and later drew the attention of international donors who have pitched in to support the efforts to build the infrastructure.
Village of Boatmen
The village is inhabited mostly by boatmen, who work as daily wage labourers. Interestingly, the shooting for Hindi films Bandit Queen and Paan Singh Tomar, based on the Chambal dacoits, was done near Rajghat.
An old and single-room government primary school in a dilapidated condition – the only educational institution in Rajghat – has given way to a smart school with two classrooms, an office room and a small verandah, constructed in the shape of train coaches. The installation of a smart board in the school has stopped the student dropouts.
Dr. Parashar told The Hindu that the Indian-Norwegian Community carried out crowdfunding to support the 'Save Rajghat Campaign' through a project called Saksham. The school, which was on the verge of closure because of decline in admissions, is now functioning with a newly installed smart board. It has over 30 students enrolled, and new admissions are coming in the academic session which started on July 1.
Dr. Parashar said his campaign would now focus on 'dignified life' for villagers, with a motorable road, clean drinking water and a fully functional hospital.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
23 minutes ago
- Time of India
More than a number: Understanding obesity through epidemiology
Obesity is one of the risk factors of sedentary lifestyle. (Pic credits- Istock. Image used for representative purpose only) Did you know that according to the World Health Organization, about one in 8 people are suffering from obesity globally? Obesity is a serious, chronic condition with far-reaching health consequences. In 2022, 2.5 billion people were overweight and among them 890 million were obese. In 2021, high body mass index (BMI) directly caused 1.6 million premature deaths from non-communicable diseases (NCDs). By 2030, more than 2.9 billion adults are expected to have a high BMI, including 1.1 billion living with obesity (BMI of 30 or higher). Notably, nearly 400 million adults will fall into obesity class II (BMI of 35 or higher), with women making up majority of this group. As excess weight becomes more common worldwide, it's clear that it has become a public health crisis. India is also facing an exponential rise in obesity with National Family Health Survey (NFHS-5) revealing that nearly one in four Indian adults aged 15-49 is overweight or obese. These numbers have increased steadily over the past two decades, driven by urbanisation, sedentary work, processed diets, and socio-economic shifts. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Esse novo alarme com câmera é quase gratuito em Uberaba (consulte o preço) Alarmes Undo Hence, tackling obesity means confronting these root causes head-on, not just managing its effects. Understanding the epidemiology of obesity is key to turning the tide. Epidemiology of obesity Epidemiology, the study of disease patterns in populations, is pivotal in understanding dynamics of weight. It studies behaviours, environments, and biological changes to understand broader health trends. When applied to weight loss, epidemiology helps distinguish between beneficial, intentional changes and those that reflect deeper, systemic issues. It helps in identifying risk factors like diet, activity, and genetics; tracking weight trends to reveal broader influences; evaluating the success of weight management strategies; shaping targeted public health interventions; and assessing how weight changes impact overall health. Key areas of this epidemiological research span several interconnected fields. Obesity epidemiology focuses on understanding how widespread obesity is, how it is distributed across populations, and the various risk factors that contribute to it. Understanding the epidemiology of obesity is important as it is a gateway to multiple life-threatening conditions. These include type 2 diabetes, heart disease, stroke, osteoarthritis, chronic back pain, sleep apnea, and several types of cancer such as breast, colon, and pancreatic. It impairs insulin function, strains the cardiovascular system, damages joints, and disrupts normal breathing during sleep. Far beyond excess weight, obesity acts as a catalyst for a cascade of life-threatening illnesses that affect nearly every organ system. The 'skinny-fat' phenomenon A unique concern in India is the 'thin-fat' phenotype, where individuals appear lean but have high body fat percentages and low muscle mass. This condition increases susceptibility to metabolic disorders like type 2 diabetes and cardiovascular diseases. Abdominal obesity affects 40% of women and 12% of men in India. Among women aged 30 to 49, the data shows that 5 to 6 out of every 10 women fall into this high-risk category. Therefore, in India, waist circumference is considered a more accurate indicator of health risks compared to BMI alone. The waist circumference-to-height ratio is also commonly used to assess abdominal obesity. The numbers are staggering, and the trajectory is rising. Obesity is preventable and, in many cases, reversible. Moreover, losing excess weight can have multitudes of benefits as even a modest reduction (5-10%) in body weight can lead to measurable improvements in blood pressure and cholesterol levels. Therefore, greater weight loss will lead to greater health benefits. In countries like India, where obesity is rising in tandem with economic growth, the challenge is to balance development with health. This involves coordinated action across sectors such as healthcare, education, agriculture, and urban planning. To change the future, we must start by recognising obesity not as a failure of willpower but as a complex, chronic disease that demands serious action. Authored by: Dr Nitin Kapoor Certain lifestyle habits may develop metabolic syndrome: Study
News18
an hour ago
- News18
Wegovy Makes Strong Debut, Mounjaro Leads As Weight Loss Drug Market Heats Up
Last Updated: The booming uptake of anti-obesity drugs in India is further underscored by rising momentum of Eli Lilly's Mounjaro, which has shown a sharp month-on-month increase in consumption Blockbuster weight loss drug Wegovy, developed by Novo Nordisk, officially entered the Indian pharmaceutical market in the last week of June and ended up registering strong sales of Rs 2.53 crore in its first week, data shows. According to the data by pharma research firm Pharmatrak, a total of 1,788 units were sold across five dosage strengths, indicating a swift adoption among prescribers and patients alike. Wegovy's sales data is for the period between June 24 and June 30. The Danish drugmaker's Wegovy is available in five dosage strengths ranging from 0.25 mg to 2.4 mg, administered via prefilled syringes. While the recommended starting dose for the new drug is 0.25 mg, sales data shows an unusual trend with strong demand across all dose strengths, suggesting prior patient exposure or rapid titration. 'The medication follows a titration schedule, with doses increasing every four weeks. However, data reveals that all strengths have seen uptake from the start, suggesting some patients may have previously been on semaglutide therapy through imported channels even before the drug's formal rollout in India," Sheetal Sapale, vice-president (commercial), Pharmatrak, told News18. Top endocrinologists agreed that while some patients were already importing Wegovy or Ozempic for consumption, the others are probably transitioning from oral semaglutide tablet Rybelsus to injectable Wegovy now. 'Some patients were already importing Ozempic or Mounjaro," said Dr Anoop Misra, chairman at Fortis C-DOC Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology. Dr Ambrish Mithal, chairman and head, endocrinology and diabetes at Max Healthcare, pointed at another possibility. 'While many people were already importing and consuming, there will be a subset of people who must be trying to transition from oral tablets to injectable semaglutide. Rybelsus was already available in India and many people were consuming it already and now probably, they are shifting to injectable doses. In this case, they can start from medium doses such as 0.5 mg or 1mg." Wegovy V/s Mounjaro The booming uptake of anti-obesity drugs in India is further underscored by the rising momentum of Eli Lilly's Mounjaro (tirzepatide), which has shown a sharp month-on-month increase in consumption, with over 37,000 units sold in June, data shows. The report by Pharmatrak suggests strong adherence to prescribed dosing schedules and parallel onboarding of new patients. Tirzepatide, despite launching just a quarter ago, has already captured 8 per cent market share, joining semaglutide (Wegovy's active ingredient) to collectively dominate 75 per cent of the anti-obesity drug market by value. According to the data, the overall anti-obesity segment has grown nearly five-fold in five years, driven by better awareness, affordability, and willingness to try newer GLP-1-based therapies, compared to older agents like Orlistat that had limited efficacy and acceptability in the Indian context.
Hans India
2 hours ago
- Hans India
Anti-rabies vax available in 4/5 public health facilities
New Delhi: Nearly four-fifths of the public health facilities in India have anti-rabies vaccine -- crucial to achieve the goal of rabies elimination by 2030 --, revealed a new study led by the Indian Council of Medical Research (ICMR). Ensuring accessible and affordable post-exposure prophylaxis is a crucial strategy to eliminate rabies. The new study, published in the journal 'The Lancet' Regional Health - Southeast Asia, is based on a nationwide survey of health facilities to understand the availability of anti-rabies vaccine and rabies immunoglobulin. 'We found that nearly four-fifths of the public health facilities had anti-rabies vaccine,' said corresponding author Dr. Manoj Murhekar, Director of the ICMR-National Institute of Epidemiology (ICMR-NIE). According to data from the ICMR, India has recorded a 75 per cent reduction in rabies-related deaths. Yet, India is one of the leading countries in the world for rabies fatalities as the infection claims about 5,700 lives every year. Around 9 million animal bite cases are also reported annually. The cross-sectional study across 60 districts in 15 Indian states also found considerable geographic and facility-level variations in the availability of the medications. Of the 534 health facilities surveyed, 467 (87.5 per cent) were public sector health facilities. Anti-rabies vaccine was available in 372 public sector health facilities, ranging from 60.0 per cent to 93.2 per cent in different geographic regions. The availability of anti-rabies vaccine was lowest in urban primary healthcare centres (UPHCs), while rabies immunoglobulin was available in 95 public sector health facilities, with the highest availability in southern states. The availability of rabies immunoglobulin ranged from 1.8 per cent in UPHCs to 69.2 per cent in medical college hospitals. 'The availability (of anti-rabies vaccine) was lowest in the north-east region and highest in the southern states. Two-third of the public facilities providing anti-rabies vaccine followed had adopted the dose saving intradermal regimen as recommended by the National Rabies Control Programme, while the remaining were still following the older intra-muscular regimen,' Murhekar said. 'Rabies immunoglobulin was available only in one-fifth of public health facilities. Nearly two-third of the medical college hospitals had rabies immunoglobulin available, but the availability was notably low in the public primary care facilities,' he added. The researchers noted that the non-availability of anti-rabies vaccine in the health facility on the day of the visit could lead to bite victims returning home without receiving the jab, which can undermine the efforts toward the goal of rabies elimination. The findings called for bridging the gap in the availability of anti-rabies vaccine and rabies immunoglobulin to achieve the goal of zero-dog-mediated human rabies deaths by 2030, Murhekar said.
